The biotechnology industry plays a crucial role in developing products that are both environmentally friendly and economically profitable. By adapting and modifying biological organisms, processes, and systems found in nature, biotechnology contributes to sustainable industrial development. This article explores the impact of ESG considerations in the biotechnology sector, highlighting the environmental benefits, social contributions, and governance practices that shape the industry’s trajectory.
Environmental Advancements in Biotechnology
Biotechnology has the potential to revolutionize agriculture and contribute to sustainable food production. By increasing crop yields and designing more efficient crops, biotechnology can manipulate primary energy flows and reduce the use of fossil fuels in agricultural systems. This technology also helps address environmental challenges such as deforestation and soil erosion. Additionally, biotechnology enables resource recovery, recycling, and hazardous waste disposal, offering environmentally beneficial solutions.
The COVID-19 pandemic has further showcased the positive impact of biotechnology on healthcare infrastructure. Through advancements in biotechnology, the pharmaceutical industry has expanded opportunities for drug development and vaccine manufacturing. These developments have improved healthcare infrastructure, enabling better diagnosis, treatment, and reduction of the seroprevalence rate of COVID-19 infections.
Is your business one of participants to the Biotechnology Industry? Contact us for focused consultation around ESG Investing, and help you build sustainable business practices
ESG Trends
The biotechnology industry is at the forefront of environmental innovations aimed at increasing efficiency and promoting sustainability. Governments, public institutions, and private organizations alike are investing heavily in environmental biotechnology to protect biodiversity and address waste treatment and bioremediation challenges. This sector has witnessed significant advancements in waste treatment and pollutant removal methods, replacing inefficient and costly chemical-based approaches.
Moreover, industrial biotechnology extends beyond biofuel production. It has transformed various industrial processes, ranging from the production of detergents and textiles to vitamins and antibiotics. By conserving natural resources, reducing costs, and accelerating the development of greener products, industrial biotechnology contributes to sustainable practices.
The biotechnology sector also aligns with the United Nations’ Sustainable Development Goals (SDGs) to achieve sustainable development solutions. It addresses SDG 1 by offering agricultural biotechnology solutions that help farmers increase their incomes and reduce vulnerability to climate change. In pursuit of SDG 2, biotechnology produces healthier and more productive crops, reducing food waste and extending shelf life. SDG 3 benefits from biotechnology’s development of medicines, vaccines, and tools to prevent and contain epidemics and improve global healthcare quality. Biotechnology also supports SDG 6 by purifying water using bacteria and plants, ensuring clean water and sanitation. Additionally, biotechnology innovations contribute to SDG 8 by providing economic opportunities through the development of medicines and agricultural products. SDG 9 is advanced through investments in biotechnology parks, research and development infrastructure, and partnerships with international organizations.
ESG Risks and Challenges
While biotechnology offers numerous benefits, it also presents risks and challenges. The commercial availability of biotechnology has led to increased exploitation of biological resources for various applications, including food productivity enhancement, disease treatment, and energy generation. However, these applications have been associated with undesirable outcomes such as diminished species biodiversity, agrobiodiversity loss, environmental contamination, and appropriation of biodiversity through intellectual property rights and patents in developing countries.
The use of genetic engineering and antibiotic marker genes in biotechnology can contribute to the problem of antibiotic-resistant bacteria. Genetic modifications in crops have raised concerns about the loss of natural farming practices, altering the very essence and taste of food. To ensure sustainable practices, biotechnology must prioritize natural and ethical farming methods that do not solely rely on agrochemicals and do not exploit humans, animals, and natural flora and fauna.
The Growth of the Biotechnology Market
The global biotechnology market is projected to reach USD 1,023.92 billion by 2021, with a compound annual growth rate (CAGR) of 13.9% from 2022 to 2030. Governments worldwide are supporting this market by modernizing regulatory frameworks, improving approval processes and reimbursement policies, and standardizing clinical trials. Collaborations between government bodies and biotech companies focus on research and development to develop drugs and vaccines for various diseases.
Key Companies
- AstraZeneca
- Gilead Sciences, Inc.
- Bristol-Myers Squibb
- Sanofi
- Biogen
- Abbott Laboratories
- Pfizer, Inc.
- Amgen, Inc.
- Novo Nordisk A/S
- Merck KGaA
- Johnson & Johnson Services, Inc.
- Novartis AG
- F. Hoffmann-La Roche Ltd.
- Lonza
Key Benefits of the Biotechnology Industry ESG Thematic Report
The Biotechnology Industry ESG Thematic Report offers several key benefits to its readers. It provides a comprehensive understanding of macro-economic factors, policies, regulations, and innovations impacting the biotechnology industry globally. The report delves into infrastructure developments and ESG issues relevant to the industry, allowing businesses to identify risks and opportunities among leading players. Moreover, it offers clear insights into company actions, progress, and impact, empowering investors to make informed decisions.
Browse more ESG Thematic Reports from the Healthcare Sector, published by Astra – ESG Solutions
About Astra – ESG Solutions By Grand View Research
Astra is the Environmental, Social, and Governance (ESG) arm of Grand View Research Inc. – a global market research publishing & management consulting firm.
Astra offers comprehensive ESG thematic assessment & scores across diverse impact & socially responsible investment topics, including both public and private companies along with intuitive dashboards. Our ESG solutions are powered by robust fundamental & alternative information. Astra specializes in consulting services that equip corporates and the investment community with the in-depth ESG research and actionable insight they need to support their bottom lines and their values. We have supported our clients across diverse ESG consulting projects & advisory services, including climate strategies & assessment, ESG benchmarking, stakeholder engagement programs, active ownership, developing ESG investment strategies, ESG data services, build corporate sustainability reports. Astra team includes a pool of industry experts and ESG enthusiasts who possess extensive end-end ESG research and consulting experience at a global level.
Need expert consultation around identifying, analyzing and creating a plan to mitigate ESG risks related to your business? Share your concerns and queries, we can help!
